• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Altimmune (ALT)

Common Shares
Sell: $5.25|Buy: $5.32|Change: 0.07 (-1.31%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Address

555 Madison Avenue, 5th floor
New York
NY
USA
10022

Telephone

+1 917 3222571

Website

https://www.altimmune.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Altimmune Inc Third Quarter Earnings Conference Call for 20262026-11-06T08:30:00
Altimmune Inc Third Quarter Earnings Results for 20262026-11-06T00:00:00
Altimmune Inc Annual General Meeting for 20262026-09-25T08:30:00
Altimmune Inc Second Quarter Earnings Conference Call for 20262026-08-12T08:30:00
Altimmune Inc Second Quarter Earnings Results for 20262026-08-12T00:00:00
Altimmune Inc First Quarter Earnings Conference Call for 20262026-05-08T08:30:00
Altimmune Inc First Quarter Earnings Results for 20262026-05-08T00:00:00
Altimmune Inc Fourth Quarter Earnings Conference Call for 20252026-02-27T08:30:00
Altimmune Inc Annual Report for 20252026-02-27T00:00:00
Altimmune Inc Fourth Quarter Earnings Results for 20252026-02-27T00:00:00
Piper Sandler 37th Annual Healthcare Conference2025-12-03T14:30:00

Previous key dates

NameKey Date
Piper Sandler 37th Annual Healthcare Conference2025-12-03T14:30:00
Jefferies Global Healthcare Conference2025-11-20T09:30:00
Stifel 2025 Healthcare Conference2025-11-12T10:00:00
Altimmune Inc Third Quarter Earnings Conference Call for 20252025-11-06T08:30:00
Altimmune Inc Third Quarter Earnings Results for 20252025-11-06T00:00:00
H.C. Wainwright Liver Disease Virtual Conference2025-10-21T07:00:00
Stifel 2025 Virtual Cardiometabolic Forum2025-09-30T10:30:00
Altimmune Inc Annual General Meeting for 20252025-09-25T08:30:00
Morgan Stanley Global Healthcare Conference2025-09-10T07:45:00
H.C. Wainwright Global Investment Conference2025-09-09T08:30:00
Altimmune Inc Second Quarter Earnings Conference Call for 20252025-08-12T08:30:00
Altimmune Inc Second Quarter Earnings Result for 20252025-08-12T00:00:00
Pemvidutide IMPACT 24-week Data Readout Webcast2025-06-26T08:30:00
Jefferies Global Healthcare Conference2025-06-04T09:55:00
H.C. Wainwright 3rd Annual BioConnect Investor Conference2025-05-20T10:00:00
Altimmune Inc First Quarter Earnings Conference Call for 20252025-05-08T08:30:00
Altimmune Inc First Quarter Earnings Results for 20252025-05-08T00:00:00
Altimmune to Participate in the Citizens Life Sciences Conference2025-05-07T09:30:00
Leerink Global Healthcare Conference2025-03-10T15:40:00
Altimmune Inc Fourth Quarter Earnings Conference Call for 20242025-02-27T08:30:00
Altimmune Inc Annual Report for 20242025-02-27T00:00:00
Altimmune Inc Fourth Quarter Earnings Result for 20242025-02-27T00:00:00
Guggenheim SMID Cap Biotech Conference2025-02-05T09:30:00
Piper Sandler Annual Healthcare Conference2024-12-04T15:30:00
Annual Evercore HealthCONx Conference2024-12-03T10:50:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.